AlphaFold predicted structure
SUMF1 · Q8NBK3

Mean pLDDT
83.6/ 100
Confident
374 residues
Confidence breakdown
- Very high(≥ 90)71%
- Confident(70–90)5%
- Low(50–70)4%
- Very low(< 50)20%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
sulfatase modifying factor 1
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalHydrocephalus
BIALLELIC, autosomal or pseudoautosomalInherited white matter disorders
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalLysosomal storage disorder
BIALLELIC, autosomal or pseudoautosomalRetinal disorders
BIALLELIC, autosomal or pseudoautosomal+6 more panels — install the extension to see the full list inline on any page.
Multiple sulfatase deficiency
mucosulfatidosis
spinocerebellar ataxia type 15/16
inherited retinal dystrophy
hereditary disease
placenta praevia
alcohol drinking
hypertrophic cardiomyopathy
lower respiratory tract disorder
tooth disorder
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Formylglycine-generating enzyme
Oxidase that catalyzes the conversion of cysteine to 3-oxoalanine on target proteins, using molecular oxygen and an unidentified reducing agent (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:16368756, PubMed:21224894, PubMed:25931126). 3-oxoalanine modification, which is also named formylglycine (fGly), occurs in the maturation of arylsulfatases and some alkaline phosphatases that use the hydrated form of 3-oxoalanine as a catalytic nucleophile (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:16368756, PubMed:25931126). Known substrates include GALNS, ARSA, STS and ARSE (PubMed:12757706, PubMed:15657036, PubMed:15907468)
SUMF1 · Q8NBK3

Mean pLDDT
83.6/ 100
Confident
374 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0